Moreover, in the same study, a greater quantity of tumor-resident CD69+CD103+CD8+ T cells was linked to better melanoma-specific survival in stage III patients not receiving adjuvant anti-PD-1 [40]. This evidence concerns the gene PDCD1 and melanoma.